HeartSciences (NASDAQ:HSCS) Trading Up 11.6% – Still a Buy?

HeartSciences Inc. (NASDAQ:HSCS) shares traded up 11.6% on Friday . The company traded as high as $2.87 and last traded at $2.80. Approximately 145,570 shares were traded during mid-day trading, an increase of 78% from the average session volume of 81,638 shares. The stock had previously closed at $2.51.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartSciences in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, HeartSciences has an average rating of “Hold” and an average target price of $8.00.

HeartSciences Stock Performance

The company has a market capitalization of $10.92 million, a price-to-earnings ratio of -0.71 and a beta of 1.79. The stock’s fifty day simple moving average is $2.39 and its two-hundred day simple moving average is $2.35.

HeartSciences (NASDAQ:HSCS) last announced its quarterly earnings data on Thursday, July 23rd. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.22). On average, equities analysts anticipate that HeartSciences Inc. will post -3.04 EPS for the current fiscal year.

Institutional Investors Weigh In On HeartSciences

A hedge fund recently raised its stake in HeartSciences stock. DRW Securities LLC increased its position in shares of HeartSciences Inc. (NASDAQ:HSCS) by 13.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 95,065 shares of the company’s stock after buying an additional 11,455 shares during the period. DRW Securities LLC owned 2.99% of HeartSciences worth $294,000 at the end of the most recent reporting period. Institutional investors own 17.24% of the company’s stock.

About HeartSciences

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non?invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high?fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high?frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.